{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', \"15. Beck's Depression Index score of > 22 (indicates clinically depressed\", 'state)', '16. Allergies to any of the medications to be used during the procedures,', 'including known hypersensitivity (allergy) to hyaluronate preparations', 'or', 'allergies to avian or avian-derived products (including eggs, feathers, or', 'poultry)', '17. Active joint infection or systemic or localized infection at needle entry', 'sites (subject may be considered for inclusion once infection is', 'resolved)', '18. History of uncontrolled coagulopathy, ongoing coagulation treatment', 'that cannot be safely interrupted for procedure, or unexplained or', 'uncontrollable bleeding that is uncorrectable', '19. Identifiable anatomical variability that would materially alter the', 'procedure as described in the protocol', '20. Within the preceding 2 years, subject has suffered from active narcotic', 'addiction, substance, or alcohol abuse', '21. Current prescribed opioid medications greater than 60 morphine', 'equivalent daily opioid dose', '22. Uncontrolled immunosuppression (e.g. AIDS, cancer, diabetes, etc.)', '23. Subject currently implanted with pacemaker, stimulator or defibrillator.', '24. Participating in another clinical trial/investigation within 30 days prior to', 'signing informed consent', '25. Subject unwilling or unable to comply with follow up schedule or', 'protocol requirements', 'Safety Parameters /', 'Safety Endpoint: Proportion of subjects experiencing adverse events through', 'Endpoints:', 'final follow up.', 'Version #: 4.0', 'Page 6 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'Table of Contents', '1', 'General Information', '2', '2', 'Synopsis', '4', '3', 'List of Abbreviations and Definition of Terms', '10', '4', 'Introduction', '11', '4.1', 'Background / Study Population', '11', '4.2', 'Product Descriptions and Intended Use', '13', '4.3', 'Exempt studies Determination', '14', '4.4', 'Summary of Prior Investigations', '14', '4.5', 'Rationale for Study', '15', '4.6', 'Potential Risks & Benefits', '15', '5', 'Study Objectives', '17', '6', 'Investigational Plan', '17', '6.1', 'Study Design', '17', '6.2', 'Endpoints', '18', '6.2.1', 'Primary Endpoints', '18', '6.2.2', 'Secondary Endpoints', '18', '6.2.3', 'Tertiary Endpoints', '18', '6.2.4', 'Exploratory Analyses', '18', '6.3', 'Measures to Minimize/Avoid Bias', '18', '6.4', 'Duration of Subject Participation', '19', '6.5', 'Study-Stopping Criteria', '19', '6.6', 'Test Article Storage, Administration, & Accountability', '19', '6.6.1', 'Instructions for Use', '19', '6.6.2 Product Labeling, Packaging, and Storage', '19', '6.6.3', 'Treatment Assignment', '20', '6.6.4', 'Procedural Description', '20', '6.6.5', 'Test Article/Supply Accountability', '22', '7', 'Subject Selection', '22', '7.1', 'Inclusion Criteria', '22', '7.2', 'Exclusion Criteria', '23', '8', 'Study Procedures', '24', '8.1', 'Center Readiness', '24', '8.2', 'Informed Consent Procedures', '24', '8.3', 'Electronic Case Report Forms', '25', '8.4', 'Measures and Methods of Assessment', '25', 'Version #: 4.0', 'Page 7 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '8.4.1', 'Demographic information', '25', '8.4.2', 'Index Knee', '25', '8.4.3', 'Radiographic Evaluation', '25', '8.4.4 Subject Reported Clinical Symptoms of Chronic Knee Pain', '25', '8.4.5', 'Combined Investigator/Subject Reported Outcomes', '26', '8.4.6', 'Intraoperative Radiographic Assessment', '26', '8.4.7', 'Post-Treatment Care', '26', '8.4.8 Subject-Reported Quality of Life Outcome Measures', '26', '9', 'Schedule of Assessments', '27', '10', 'Procedures by Visit', '27', '10.1', 'Visit 1 - Screening / Randomization', '27', '10.2', 'Visit 2 - Index Treatment (Day 0)', '28', '10.3', 'VISIT 3-6 - FOLLOW-UP ASSESSMENTS', '28', '10.4', 'Discontinuation / Early Termination (ET)', '29', '10.5', 'Crossover visit (visit 5a)', '30', '11', 'Adverse Event Reporting', '31', '11.1', 'Adverse Events (AE) Assessment', '31', '11.1.1 Definitions and Classification', '31', '11.2', 'Severity of Adverse Events', '32', '11.3', 'Relationship of Adverse Events', '32', '11.4', 'Reporting Adverse Events', '33', '11.5', 'Reporting Serious Adverse Events', '34', '11.6', 'Clinical Safety Monitoring', '34', '12', 'Statistical Methods and Data Analysis', '35', '12.1', 'Determination of Sample Size', '35', '12.1.1 Disposition of Subjects', '35', '12.1.2 Protocol Deviations', '36', '12.2', 'Dataset Definitions', '36', '12.2.1', 'Safety Set', '36', '12.2.2 Full-Analysis Set', '36', '12.2.3 Per-Protocol Set', '36', '12.3', 'Effectiveness Parameter', '37', '12.3.1 Primary Effectiveness Parameter', '37', '12.3.2 Secondary Effectiveness Parameters', '37', '12.3.3 Tertiary Effectiveness Parameter', '37', '12.3.4 Exploratory Analysis', '37', '12.4', 'General Considerations', '37', '12.5', 'Demographics, Baseline Characteristics, and Concomitant Medications', '38', 'Version #: 4.0', 'Page 8 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}